We earn commissions from the providers listed here. No provider buys a position, a rating, or a listing. The order is set by hand, and we do not claim it is independent of what we earn. Advertising Disclosure
Complete 2026 Comparison for Erectile Dysfunction, Testosterone Replacement Therapy
Between Maximus and Taurus Meds, you're comparing two solid options for Erectile Dysfunction and Testosterone Replacement Therapy, where Maximus lets you choose from Sildenafil, Tadalafil, or Vardenafil with HSA/FSA savings of 20-35%, while Taurus Meds counters with a proprietary 4-in-1 formula and an at-home T-test that gives you results in 5 minutes. Both ship your medication free to your door.
Go with Maximus if you want to use HSA or FSA dollars to cut costs and pick your exact ED or TRT medication format yourself.
You want Taurus Meds if getting pre-approved in 3 minutes and skipping any long intake process is your top priority.
Choose Maximus if you value format flexibility and HSA/FSA savings across ED and TRT treatments. Choose Taurus Meds if you're in a rush or want that reported 200-500% testosterone improvement with no long-term contract locking you in. Both brands rate above 8.9, and both are available in at least 49 states. Solid options across the board.
Maximus specializes in testosterone replacement therapy and erectile dysfunction treatment for men, offering injectable TRT, enclomiphene, and ED medications through a streamlined telehealth platform.
Taurus Meds offers online testosterone replacement therapy and erectile dysfunction treatment with a focus on affordable pricing and a streamlined 3-minute assessment process.
| Feature | Maximus | Taurus Meds |
|---|---|---|
| Rating | 9.2/10 | 9.6/10 |
| Founded | 2021 | 2023 |
| Free Consultation | No | No |
| Free Shipping | Yes | Yes |
| Accepts Insurance | No | No |
| HSA/FSA Accepted | Yes | No |
| Mobile App | No | No |
| Consultation Type | Video, Asynchronous | Asynchronous |
| Shipping Time | 3-5 business days | 3-5 business days |
| Treatment | | |
|---|---|---|
| Erectile Dysfunction | $49/mo$49-$99/mo | $12.99/dose$12.99/dose |
Choose Maximus if you:Choose Taurus Meds if you:It depends on your needs. Maximus excels in TRT with multiple delivery options and a 9.2 rating in our rankings. Taurus Meds may be better if you need broader treatment categories or different pricing structures.
Maximus TRT starts at $99.99/month. Compare this with Taurus Meds's pricing to find the best value for your specific treatment needs.
Yes, you can switch providers at any time. Maximus will conduct their own assessment including bloodwork through LabCorp or Quest Diagnostics.
Medical Disclaimer: The information on this page is for educational purposes only and is not medical advice. Always consult with a licensed healthcare provider before starting any treatment. Read our full medical disclaimer.
Regulatory noticeRegulatory note (verified August 22, 2026): A May 2026 review of maximustribe.com led the FDA to issue Maximus Health, Inc. warning letter MARCS-CMS 730095 on June 8, 2026. The language quoted here concerns effect and sourcing rather than ingredient comparison: "Clinically studied ingredients," "Clinically studied to help patients...," and "Proven to lose weight effectively," alongside a statement that the compounded products come from "FDA approved pharmacies." On that last point the agency was explicit that no FDA-approved or FDA-licensed designation exists for compounding pharmacies or outsourcing facilities, so describing one that way is misleading. Both findings were cited as misbranding under FD&C Act 502(a) and 502(bb). Nothing in FDA’s index records a close-out, so we log the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): The FDA reviewed struthealth.com in December 2025 and, on February 20, 2026, issued Strut Health, LLC a warning letter, MARCS-CMS 721448. It raises two separate problems. Pictured product labels carry the "Strut" name, which the agency said represents Strut as the compounder of the semaglutide and tirzepatide products when it is not. Three site claims are also quoted, among them "Generic Zepbound, Mounjaro" and "Semaglutide is the active ingredient in the brand medications." Because compounded drugs hold no FDA approval, the FDA said wording of that kind implies one, and it cited misbranding under sections 502(a) and 502(bb) of the FD&C Act. FDA’s warning letter index shows no response letter and no close-out letter, so we treat the matter as open. Read the FDA letter
Regulatory noticeRegulatory note (verified August 22, 2026): On September 9, 2025 the FDA sent Hims & Hers Health, Inc. a warning letter covering the Hims brand, MARCS-CMS 716567, drawn from a review of hims.com the previous month. Two lines about compounded semaglutide are quoted in it: "Same active ingredient as Ozempic and Wegovy" and "Clinically proven ingredients." Compounded drug products are not FDA-approved, and the agency said phrasing of this sort suggests otherwise, which is what makes the products misbranded under FD&C Act sections 502(a) and 502(bb). A companion letter went to the same company that day for its Hers brand. No close-out letter appears in FDA’s index; treat this as open. Read the FDA letter
